Dmitrij Hristodorov, partner at Forbion, told the Sachs Forum audience there were clear signs of a comeback for the cardiovascular/cardiometabolic (CVM) market. He highlighted new drug approvals in dyslipidemia , hypertension, diabetes, obesity and cardiomyopathy as key indications that there is more to come in the CVM space in the coming few years. The panelists discussed historic and new challenges in the market, regulatory rigor, and the availability of different modalities to treat CVM diseases.
A Cardio Comeback: CV Market Back In The Spotlight
Industry experts at the recent Sachs Biotech in Europe Forum discussed the renaissance in the cardiovascular and cardiometabolic markets, which are gaining momentum on the back of recent approvals, deal activity and new company launches.
More from Market Intelligence
• By
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
• By
Regenxbio is riding a wave these days, with all three of its clinical-stage programs set to reach critical milestones this year and recent positive news on its DMD gene therapy, just as Sarepta suffered a setback with a death related to its DMD treatment. In Vivo spoke with CEO Curran Simpson about the company’s plans and strategic decisions.
• By
From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.
• By
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
More from In Vivo
• By
Bringing AI and digital healthtech innovation to patients works most efficiently via a three-way partnership in which clinicians and cloud services have equal weighting with a powerhouse innovator, Royal Philips told In Vivo during ECR 2025.
• By
Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.
• By
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.